SCHEMBL6454344

SCHEMBL6454344

FC(F)(F)c1cccnc1-c1noc(-c2cccc3ccccc23)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.59
KDM4E B2RXH2 5/20 0.59
ALDH1A1 P00352 5/20 0.59
HPGD P15428 5/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
HSD17B10 Q99714 4/20 0.59
NPC1 O15118 4/20 0.59
MAPK1 P28482 3/20 0.59
TP53 P04637 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
ATM Q13315 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
RAB9A P51151 3/20 0.53
LMNA P02545 1/20 0.53
GAA P10253 2/20 0.44
S1PR1 P21453 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450253 0.81 SMN1; SMN2 (0.63) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6448845 0.80 KDM4E (0.65) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6454404 0.79 KDR (0.39) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6449956 0.77 SMN1; SMN2 (0.47) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6450875 0.76 MAPT (0.56) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL28133798 0.74 SMN1; SMN2 (0.77) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4193214 0.74 SMN1; SMN2 (1.00) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6454145 0.74 CHUK (0.41) MAPTKDM4EHPGDSMN1; SMN2NPC1
SCHEMBL7049003 0.72 SMN1; SMN2 (0.62) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6449958 0.72 NPC1 (0.44) MAPTKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC MAPT 2805/4885KDM4E 3106/4885ALDH1A1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.